Efficacy and tolerability of different brands of intravenous immunoglobulin in the maintenance treatment of chronic immune-mediated neuropathies

2016 ◽  
Vol 21 (2) ◽  
pp. 82-84 ◽  
Author(s):  
Francesca Gallia ◽  
Claudia Balducci ◽  
Eduardo Nobile-Orazio
Keyword(s):  
Intravenous Immunoglobulin ◽  
Maintenance Treatment ◽  
Immune Mediated

Successful treatment of infliximab-associated immune-mediated sensory polyradiculopathy with intravenous immunoglobulin

2013 ◽  
Vol 20 (11) ◽  
pp. 1618-1619 ◽  
Author(s):  
Hiroya Naruse ◽  
Yu Nagashima ◽  
Risa Maekawa ◽  
Takafumi Etoh ◽  
Ayumi Hida ◽  
...  
Keyword(s):  
Intravenous Immunoglobulin ◽  
Successful Treatment ◽  
Immune Mediated

Mechanisms of Action of Intravenous Immunoglobulin (IVIg) in Immune-Mediated Diseases

1999 ◽  
pp. 383-394
Author(s):  
K. A. Nagendra Prasad ◽  
Michel D. Kazatchkine ◽  
Srinivas V. Kaveri
Keyword(s):  
Intravenous Immunoglobulin ◽  
Mechanisms Of Action ◽  
Immune Mediated

scholarly journals Clinical Responses to Rituximab in a Case of Neuroblastoma with Refractory Opsoclonus Myoclonus Ataxia Syndrome

2012 ◽  
Vol 2012 ◽  
pp. 1-4 ◽  
Author(s):  
Samin Alavi ◽  
Ali Kord Valeshabad ◽  
Borhan Moradveisi ◽  
Ali Aminasnafi ◽  
Mohammad Taghi Arzanian
Keyword(s):  
Eye Movements ◽  
Intravenous Immunoglobulin ◽  
Severity Score ◽  
Adrenocorticotropic Hormone ◽  
Efficacy And Safety ◽  
Imaging Studies ◽  
Immune Mediated ◽  
Clinical Responses ◽  
Ataxia Syndrome ◽  
Refractory Case

Opsoclonus myoclonus ataxia syndrome (OMS) is a rare neurologic syndrome. In a high proportion of children, it is associated with neuroblastoma. The etiology of this condition is thought to be immune mediated. In children, immunotherapy with conventional treatments such as corticosteroids, intravenous immunoglobulin, adrenocorticotropic hormone, and even antiepileptic drugs has been tried. Recently rituximab has been used safely for refractory OMS in children with neuroblastoma. Our patient was a 3.5-year-old girl referred for ataxia and dancing eye movements starting since 1.5 years ago. She was diagnosed with neuroblastoma on imaging studies on admission. The OMS was refractory to surgical resection, chemotherapy, corticosteroids, and intravenous immunoglobulin. Patient received rituximab simultaneously with chemotherapy. The total severity score decreased by 61.1% after rituximab. Patient's ataxia markedly improved that she was able to walk independently after 6 months. Our case confirmed the clinical efficacy and safety of rituximab in a refractory case of OMS.

Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin

Blood ◽  
2003 ◽  
Vol 101 (2) ◽  
pp. 758-765 ◽  
Author(s):  
Jagadeesh Bayry ◽  
Sébastien Lacroix-Desmazes ◽  
Cedric Carbonneil ◽  
Namita Misra ◽  
Vladimira Donkova ◽  
...  
Keyword(s):  
Dendritic Cells ◽  
T Cell ◽  
Autoimmune Diseases ◽  
Intravenous Immunoglobulin ◽  
T Cell Activation ◽  
Cell Activation ◽  
Cell Activity ◽  
Interleukin 12 ◽  
Immune Mediated ◽  
And Function

Normal immunoglobulin G for therapeutic use (intravenous immunoglobulin [IVIg]) is used in an increasing number of immune-mediated conditions, including acute and chronic/relapsing autoimmune diseases, transplantation, and systemic inflammatory disorders. Several mutually nonexclusive mechanisms of action account for the immunoregulatory effects of IVIg. Although IVIg inhibits T-cell proliferation and T-cell cytokine production, it is unclear whether these effects are directly dependent on the effects of IVIg on T cells or they are dependent through the inhibition of antigen-presenting cell activity. Here, we examined the effects of IVIg on differentiation, maturation, and function of dendritic cells (DCs). We show that IVIg inhibits the differentiation and maturation of DCs in vitro and abrogates the capacity of mature DC to secrete interleukin-12 (IL-12) on activation while enhancing IL-10 production. IVIg-induced down-regulation of costimulatory molecules associated with modulation of cytokine secretion resulted in the inhibition of autoreactive and alloreactive T-cell activation and proliferation. Modulation of DC maturation and function by IVIg is of potential relevance to its immunomodulatory effects in controlling specific immune responses in autoimmune diseases, transplantation, and other immune-mediated conditions.

scholarly journals Home IVIG for CIDP: A Focus on Patient Centred Care

2013 ◽  
Vol 40 (3) ◽  
pp. 384-388 ◽  
Author(s):  
Hans D. Katzberg ◽  
Vilija Rasutis ◽  
Vera Bril
Keyword(s):  
Intravenous Immunoglobulin ◽  
Maintenance Treatment ◽  
Clinical Status ◽  
Hospital Setting ◽  
Ivig Treatment ◽  
Serious Adverse Events ◽  
Home Based ◽  
Home Infusion ◽  
Post Infusion ◽  
Almost All

Objective:To determine the safety and tolerability of home-based intravenous immunoglobulin (IVIG) (Gamunex) as maintenance treatment in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) in Canada.Methods:We enrolled ten subjects with CIDP who had previously received IVIG in the hospital setting to receive the comparable IVIG dose (1-2 g/kg/month) in the home for six months. The patients were evaluated in the clinic at three months and at six months to evaluate their clinical status as well as the safety and tolerability of IVIG.Results:All subjects tolerated home-based IVIG treatment as maintenance treatment of CIDP. There were no serious adverse events related to IVIG. Subjects did experience “anticipated” IVIG events post-infusion such as headache and fatigue, which were managed with analgesics and supportive counseling. One subject withdrew consent at end of study due to hospitalization. This event was not related to the IVIG. Another subject experienced a “flare” of CIDP symptoms near the end of the study, however, completed all visits as per protocol. All subjects expressed excellent satisfaction with the individualized therapy, and almost all (nine out of ten) patients preferred home-infusion to hospital-infusion.Conclusion:Intravenous immunoglobulin can be delivered safely and is well tolerated outside the hospital setting in Canada in patients with chronic, stable neuromuscular conditions such as CIDP who have previously tolerated IVIG in the hospital medical day Care Unit.

scholarly journals Severe Menorrhagia and Thrombocytopenia in a Patient with Pseudohypoparathyroidism

2021 ◽  
Vol 5 (2) ◽  
pp. 01-04
Author(s):  
Lily Suh
Keyword(s):  
Intravenous Immunoglobulin ◽  
Platelet Transfusion ◽  
Severe Anemia ◽  
Platelet Dysfunction ◽  
Platelet Destruction ◽  
Platelet Counts ◽  
Immune Mediated ◽  
History Of ◽  
Pseudohypoparathyroidism Ia

A 15-year-old female with a history of hypothyroidism presented with severe anemia and thrombocytopenia in the setting of prolonged menses. After further evaluation, she was diagnosed with pseudohypoparathyroidism Ia (PHPIa). Her symptoms improved after starting medications and receiving a platelet transfusion, but a few weeks later she returned with complaints of bleeding and dizziness and was found to be thrombocytopenic once again. Her platelet counts improved after administration of intravenous immunoglobulin (IVIG), leading us to believe she has a combined immune mediated platelet destruction in addition to platelet dysfunction associated with her PHPIa.

Sign in / Sign up

Export Citation Format

Share Document